These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 28604130)
1. Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. O'reilly A; Larkin J Expert Rev Anticancer Ther; 2017 Jul; 17(7):647-655. PubMed ID: 28604130 [TBL] [Abstract][Full Text] [Related]
2. The safety of nivolumab for the treatment of metastatic melanoma. O'Reilly A; Larkin J Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287 [TBL] [Abstract][Full Text] [Related]
3. Melanoma and Immune Checkpoint Inhibitors. Furue M; Ito T; Wada N; Wada M; Kadono T; Uchi H Curr Oncol Rep; 2018 Mar; 20(3):29. PubMed ID: 29569208 [TBL] [Abstract][Full Text] [Related]
4. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Nagai H; Muto M Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216 [TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482 [TBL] [Abstract][Full Text] [Related]
7. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related]
8. Checkpoint Blockade for the Treatment of Advanced Melanoma. Callahan MK; Flaherty CR; Postow MA Cancer Treat Res; 2016; 167():231-50. PubMed ID: 26601865 [TBL] [Abstract][Full Text] [Related]
9. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Marabondo S; Kaufman HL Expert Opin Drug Saf; 2017 Dec; 16(12):1347-1357. PubMed ID: 28929820 [TBL] [Abstract][Full Text] [Related]
10. Emerging targeted therapies for melanoma. Johnson DB; Pollack MH; Sosman JA Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822 [TBL] [Abstract][Full Text] [Related]
11. Cancer immunology - development of novel anti-cancer therapies. Rothschild SI; Thommen DS; Moersig W; Müller P; Zippelius A Swiss Med Wkly; 2015; 145():w14066. PubMed ID: 25668078 [TBL] [Abstract][Full Text] [Related]
12. Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. Brown ZJ; Heinrich B; Steinberg SM; Yu SJ; Greten TF J Immunother Cancer; 2017 Nov; 5(1):93. PubMed ID: 29157287 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. Decatris MP; O'Byrne KJ Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211 [TBL] [Abstract][Full Text] [Related]
15. Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management. Ahmed KA; Kim S; Harrison LB Surg Oncol Clin N Am; 2017 Jul; 26(3):515-529. PubMed ID: 28576186 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Longoria TC; Tewari KS Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741 [TBL] [Abstract][Full Text] [Related]
17. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. Aspeslagh S; Marabelle A; Soria JC; Armand JP Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760 [TBL] [Abstract][Full Text] [Related]
18. The Systemic Management of Advanced Melanoma in 2016. Heppt MV; Dietrich C; Graf SA; Ruzicka T; Tietze JK; Berking C Oncol Res Treat; 2016; 39(10):635-642. PubMed ID: 27710977 [TBL] [Abstract][Full Text] [Related]
19. Emerging growth factor receptor antagonists for the treatment of advanced melanoma. Fenton SE; Sosman JA; Chandra S Expert Opin Emerg Drugs; 2017 Jun; 22(2):165-174. PubMed ID: 28562096 [TBL] [Abstract][Full Text] [Related]